National Consultation on the Outcomes of the “Survey of Indian Pharmaceutical Enterprises for Meeting National and Global Health Needs

24 November 2017, New Delhi, India

WHO Country Office for India organized a national consultation on the outcomes of ‘Survey of Indian Pharmaceutical Enterprises for Meeting National and Global Health Needs’ on 24 November 2017 at New Delhi.

The objectives of the consultation were to: (i) disseminate the report of the pharmaceutical survey (ii) seek inputs of various stakeholders to help guide policy interventions, and (iii) identify specific areas of support by different ministries of Government of India and WHO.

The ‘Report on Survey of Indian Pharmaceutical Enterprises for Meeting National and Global Health Needs’ was launched at the consultation by Dr Arun Kumar Panda, Secretary, Ministry of Micro Small and Medium Enterprises, Government of India.

In his Inaugural address, Dr Arun Kumar Panda, Secretary, Ministry of Micro Small and Medium Enterprises said, “Government of India stands committed to promote rational procurement, and an improved access to safe, quality, affordable and efficacious medicines, including through the promotion of generics and policy options for local production, including stimulus package for micro, small, and medium enterprises in the pharmaceutical sector.”

Speaking on the occasion, Dr Henk Bekedam, WHO Representative to India said, “India, considered the pharmacy of the world, is now moving from generic drugs and vaccines to manufacturing medical products and diagnostics. Access to medicines and medical products is key to universal health coverage.”

WHO has been playing a pivotal role in promoting equitable access to quality, safe, efficacious, and affordable medical products.

Prominent dignitaries at the inaugural session were Mr Sudhanshu Pandey, Joint Secretary, Ministry of Commerce and Industry; Mr Sudhir Kumar, Joint Secretary, Ministry of Health & Family Welfare; Mr P.K. Pathak, Joint Secretary, Ministry of AYUSH,; Dr B.D. Athani, Special DGHS, Ministry of Health & Family Welfare; Dr G.N. Singh, Drugs Controller General of India, Dr Gagandeep Kang, Executive Director, THSTI; and Mr M.K. Bhardawaj, Deputy Secretary, Department of Pharmaceuticals.

The consultation was attended by senior officials of State Drug Controllers, Central Drugs Standard Control Organization; officials and experts from Ministry of Health & Family Welfare, Department of Pharmaceuticals, Ministry of Commerce and Industry, Ministry of Micro, Small and Medium Enterprises, Department of Industrial Policy and Promotion (DIPP), and NITI Aayog, among others. Eminent experts, representatives from pharmaceutical manufacturers, medical devices and pharmaceutical associations also participated in the deliberations.

Share